BioInvent International AB (publ) (STO:BINV)
Sweden · Delayed Price · Currency is SEK 27.50
+1.85 (7.21%)
May 22, 2026, 5:29 PM CET
STO:BINV Revenue
BioInvent International AB had revenue of 13.42M SEK in the quarter ending March 31, 2026, a decrease of -39.15%. This brings the company's revenue in the last twelve months to 217.86M, up 258.30% year-over-year. In the year 2025, BioInvent International AB had annual revenue of 226.50M with 406.86% growth.
Revenue (ttm)
217.86M
Revenue Growth
+258.30%
P/S Ratio
8.31
Revenue / Employee
1.95M
Employees
112
Market Cap
1.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 226.50M | 181.81M | 406.86% |
| Dec 31, 2024 | 44.69M | -26.78M | -37.47% |
| Dec 31, 2023 | 71.46M | -254.67M | -78.09% |
| Dec 31, 2022 | 326.13M | 306.74M | 1,582.45% |
| Dec 31, 2021 | 19.38M | -127.99M | -86.85% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Saniona AB | 434.40M |
| Cantargia AB | 317.21M |
| Hansa Biopharma AB | 190.49M |
| Genovis AB (publ.) | 131.09M |
| Egetis Therapeutics AB | 63.10M |
| Medivir AB | 9.01M |
| Vicore Pharma Holding AB | 3.53M |
| Xspray Pharma AB | 2.47M |
BioInvent International AB News
- 4 days ago - BioInvent to Host Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer, on May 27, 2026 - Accesswire
- 25 days ago - Resolutions at BioInvent's Annual General Meeting 2026 - Accesswire
- 25 days ago - BioInvent International AB Quarterly report: Q1 2026 - Filings
- 25 days ago - BioInvent to Host Two Key Opinion Leader Events Highlighting Progress Across Oncology Portfolio - Accesswire
- 25 days ago - BioInvent International AB: Interim Report January - March 2026 - Accesswire
- 4 weeks ago - BioInvent to Present Data of BI-1808 Plus KEYTRUDA(R) (Pembrolizumab) in Recurrent Ovarian Cancer at the 2026 ASCO Annual Meeting - Accesswire
- 7 weeks ago - BioInvent International AB Publishes Annual Report 2025 - Accesswire
- 2 months ago - BioInvent Achieves Phase 3 Milestone for HMI-115 in Endometriosis - Accesswire